stockportfolio.pro
Stocks / EWTX vs NAMS
EWTX vs NAMS
Edgewise Therapeutics, Inc. and NewAmsterdam Pharma Company N.V. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Edgewise Therapeutics, Inc. (EWTX) | NewAmsterdam Pharma Company N.V. (NAMS) | |
|---|---|---|
| Market cap | $3.7B | $3.5B |
| Revenue (latest FY) | $0 | $22.50M |
| Net income (latest FY) | $-167.79M | $-203.82M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | -905.7% |
| Return on equity | -32.1% | -29.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EWTX — free Open NAMS — freeFrequently asked questions
Which is bigger, EWTX or NAMS?
Edgewise Therapeutics, Inc. is larger by market capitalization — $3.7B versus $3.5B.
Which grows faster, EWTX or NAMS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.